Cargando…

Pulmonary hypertension and chronic lung disease: where are we headed?

Pulmonary hypertension related to chronic lung disease, mainly represented by COPD and idiopathic pulmonary fibrosis, is associated with a worse outcome when compared with patients only affected by parenchymal lung disease. At present, no therapies are available to reverse or slow down the pathologi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elia, Davide, Caminati, Antonella, Zompatori, Maurizio, Cassandro, Roberto, Lonati, Chiara, Luisi, Francesca, Pelosi, Giuseppe, Provencher, Steeve, Harari, Sergio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2019
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488824/ https://www.ncbi.nlm.nih.gov/pubmed/31636088 http://dx.doi.org/10.1183/16000617.0065-2019

Ejemplares similares

Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue
por: Caminati, Antonella, et al.
Publicado: (2019)

Ultra-rare cystic disease
por: Elia, Davide, et al.
Publicado: (2020)

Prognostic value of radiological index and clinical data in patients with COVID-19 infection
por: Elia, Davide, et al.
Publicado: (2022)

Lung Cryobiopsy for the Diagnosis of Interstitial Lung Diseases: A Series Contribution to a Debated Procedure
por: Harari, Sergio, et al.
Publicado: (2019)

Prognostic role of CHA(2)DS(2)-VASc score for mortality risk assessment in non-advanced idiopathic pulmonary fibrosis: a preliminary observation
por: Sonaglioni, Andrea, et al.
Publicado: (2023)

Severe idiopathic pulmonary fibrosis: what can be done?
por: Caminati, Antonella, et al.
Publicado: (2017)

New insights in lymphangioleiomyomatosis and pulmonary Langerhans cell histiocytosis
por: Torre, Olga, et al.
Publicado: (2017)

Charlson comorbidity index, neutrophil-to-lymphocyte ratio and undertreatment with renin-angiotensin-aldosterone system inhibitors predict in-hospital mortality of hospitalized COVID-19 patients during the omicron dominant period
por: Sonaglioni, Andrea, et al.
Publicado: (2022)

Multimodal Strategy in Localized Merkel Cell Carcinoma: Where Are We and Where Are We Heading?
por: Ricco, Gianluca, et al.
Publicado: (2021)

Where are we now and where are we headed?
por: Langan, Ewan A.
Publicado: (2023)

Recent advances in managing idiopathic pulmonary fibrosis
por: Scelfo, Chiara, et al.
Publicado: (2017)

Animal Sentience: Where are We and Where are We Heading?
por: Proctor, Helen
Publicado: (2012)

Research Integrity: Where We Are and Where We Are Heading
por: Zhaksylyk, Alikhan, et al.
Publicado: (2023)

Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences
por: Harari, Sergio, et al.
Publicado: (2015)

The Octopus Sign—A New HRCT Sign in Pulmonary Langerhans Cell Histiocytosis
por: Poellinger, Alexander, et al.
Publicado: (2022)

Articular Cartilage Repair: Where We Have Been, Where We Are Now, and Where We Are Headed
por: Grande, Daniel A., et al.
Publicado: (2013)

Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to?
por: Harari, Sergio, et al.
Publicado: (2015)

Horizons of Psychiatric Genetics and Epigenetics: Where Are We and Where Are We Heading?
por: Mostafavi Abdolmaleky, Hamid
Publicado: (2014)

Lifestyle Factors in Cancer Survivorship: Where We Are and Where We Are Headed
por: Vijayvergia, Namrata, et al.
Publicado: (2015)

Telemedicine in Urology: Where Have We Been and Where Are We Heading?
por: Symeonidis, Evangelos N., et al.
Publicado: (2023)

CAR-T cell therapy: Where are we now, and where are we heading?
por: Wang, Jia-Yi, et al.
Publicado: (2023)

Chest-CT mimics of COVID-19 pneumonia—a review article
por: Carlicchi, Eleonora, et al.
Publicado: (2021)

Pulmonary hypertension in patients with chronic myeloproliferative disorders
por: Adir, Yochai, et al.
Publicado: (2015)

Immunotherapy for Prostate Cancer: Where We Are Headed
por: Schepisi, Giuseppe, et al.
Publicado: (2017)

Editorial: Engineering Rumen Metabolic Pathways: Where We Are, and Where Are We Heading
por: Ungerfeld, Emilio M., et al.
Publicado: (2018)

Radiologic approach to axial spondyloarthritis: where are we now and where are we heading?
por: Kucybała, Iwona, et al.
Publicado: (2018)

Where are we now and where are we heading in muscle invasive bladder cancer
por: Ku, Ja Hyeon, et al.
Publicado: (2020)

THREE-DIMENSIONAL PRINTING IN ORTHOPEDICS: WHERE WE STAND AND WHERE WE ARE HEADING
por: EJNISMAN, LEANDRO, et al.
Publicado: (2021)

Future Perspectives in Pediatric Dentistry: Where are We Now and where are We Heading?
por: Rodrigues, Jonas A, et al.
Publicado: (2022)

Headache research - where are we heading?
por: Jensen, Rigmor
Publicado: (2013)

Publish or perish: Where are we heading?
por: Rawat, Seema, et al.
Publicado: (2014)

Electronic cigarettes – where are we headed?
por: Loughead, Andrew
Publicado: (2015)

Telework in health: where are we heading to?
por: de Castro, Janete Lima, et al.
Publicado: (2023)

Artificial intelligence in radiology: friend or foe? Where are we now and where are we heading?
por: Pakdemirli, Emre
Publicado: (2019)

Extracellular vesicles for liquid biopsy in prostate cancer: where are we and where are we headed?
por: Minciacchi, V R, et al.
Publicado: (2017)

Application of molecular SERS nanosensors: where we stand and where we are headed towards?
por: Jahn, Izabella J., et al.
Publicado: (2020)

Therapeutics for COVID-19: from computation to practices—where we are, where we are heading to
por: Ojha, Probir Kumar, et al.
Publicado: (2020)

Utilizing proteomics to understand and define hypertension: where are we and where do we go?
por: Delles, Christian, et al.
Publicado: (2018)

Resistant Hypertension: Where are We Now and Where Do We Go from Here?
por: Pathan, Mansur K, et al.
Publicado: (2020)

EUS-FNA in cystic pancreatic lesions: Where are we now and where are we headed in the future?
por: Lariño-Noia, Jose, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_t8fuuna49onqjah5lic3pl8885